BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
Open Access
- 25 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 109 (6), 1593-1598
- https://doi.org/10.1038/bjc.2013.318
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood, 2013
- Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent TherapyJournal of Clinical Oncology, 2011
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetBlood, 2011
- Genetic variegation of clonal architecture and propagating cells in leukaemiaNature, 2010
- Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapyHaematologica, 2010
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasmsBlood, 2010
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood, 2009
- Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseJournal of Clinical Oncology, 2009
- Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic LeukemiaScience, 2008
- In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain MutantsCancer Research, 2005